Veradermics Inc., a biopharmaceutical firm focused on hair restoration, is seeking to raise as much as $213.6 million in an initial public offering to help commercialize its hair re-growth pill.
The New Haven, Connecticut-based firm plans to market 13.4 million shares for between $14 to $16 each, according to its filing Wednesday with the US Securities and Exchange Commission. At the top of that range, Veradermics would have a market value of roughly $534 million based on the outstanding shares listed in its filing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.